MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
157.25
+0.71
+0.45%
Closed 16:35 12/02 EST
OPEN
154.68
PREV CLOSE
156.54
HIGH
157.56
LOW
154.17
VOLUME
464.21K
TURNOVER
--
52 WEEK HIGH
169.98
52 WEEK LOW
119.64
MARKET CAP
9.90B
P/E (TTM)
-499.3649
1D
5D
1M
3M
1Y
5Y
Zymeworks Announces Expiration Of Hart-Scott-Rodino Waiting Period For Zanidatamab License Agreement With Jazz Pharmaceuticals
Benzinga · 5d ago
Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zanidatamab License Deal Expires
Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zanidatamab License Deal Expires
MT Newswires · 6d ago
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including three late-breaking abstracts, will be shared at the upcoming 2022 American Epilepsy Society (AES) annual mee...
PR Newswire · 6d ago
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling
Benzinga · 6d ago
Insider Sell: Jazz Pharmaceuticals
Insider Sell: Jazz Pharmaceuticals
MT Newswires · 11/28 04:46
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling
Benzinga · 11/21 19:32
Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent
Benzinga · 11/21 13:40
Avadel Pharmaceuticals PR Confirms Favorable Ruling On Motion To Delist REMS Patent From FDA's Orange Book
Benzinga · 11/18 19:46
More
About JAZZ
Jazz Pharmaceuticals plc is a biopharmaceutical company. The Company is engaged in developing medicines for people with serious diseases. The Company’s products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, which develops for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy aged seven years of age and older; Xyrem (sodium oxybate) oral solution, which develops for the treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Epidiolex (cannabidiol) oral solution, which develops for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex in patients one year of age or older; Sunosi (solriamfetol); Sativex (nabiximols) oral solution; Zepzelca (lurbinectedin); Rylaze (recombinant Erwinia asparaginase); Vyxeos (daunorubicin and cytarabine) liposome for injection; and Defitelio (defibrotide sodium).

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.